These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 5651150)

  • 1. Immune response following simultaneous administration of attenuated trivalent poliovirus and type 4 adenovirus vaccines.
    Moldow CF; Fuld SL; Gutekunst RR
    Proc Soc Exp Biol Med; 1968 Mar; 127(3):879-82. PubMed ID: 5651150
    [No Abstract]   [Full Text] [Related]  

  • 2. Concurrent administration of live adenovirus, type 4 and live Poliovirus, type 1 vaccines.
    Chin J; Lennette EH; Schieble JH; Magoffin RL
    Am J Epidemiol; 1968 May; 87(3):633-42. PubMed ID: 5654951
    [No Abstract]   [Full Text] [Related]  

  • 3. Simultaneous oral administration of live adenovirus types 4 and 7 vaccines. Protection and lack of emergence of other types.
    Gooch WM; Mogabgab WJ
    Arch Environ Health; 1972 Dec; 25(6):388-94. PubMed ID: 4343867
    [No Abstract]   [Full Text] [Related]  

  • 4. Adenovirus arthritis.
    Panush RS
    Arthritis Rheum; 1974; 17(5):534-6. PubMed ID: 4411873
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the immune response of the rabbit to virulent and attenuated strains of type 1 poliovirus.
    Gaudin OG; Viac J; Thouvenot D; Sohier R
    Bull World Health Organ; 1974; 50(6):479-5. PubMed ID: 4376464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of immunity in man by crystalline adenovirus type 5 capsid antigens.
    Couch RB; Kasel JA; Perreira HG; Haase AT; Knight V
    Proc Soc Exp Biol Med; 1973 Sep; 143(4):905-10. PubMed ID: 4355246
    [No Abstract]   [Full Text] [Related]  

  • 7. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination.
    Sutter RW; Pallansch MA; Sawyer LA; Cochi SL; Hadler SC
    Ann N Y Acad Sci; 1995 May; 754():289-99. PubMed ID: 7625665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibody response in subjects vaccinated with a recall dose of the Sabin or Salk type vaccine].
    Squeri L; Calisto ML; Sindoni L; Mattace-Raso G
    Ann Sclavo; 1973; 15(6):569-80. PubMed ID: 4369487
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.
    Faden H; Modlin JF; Thoms ML; McBean AM; Ferdon MB; Ogra PL
    J Infect Dis; 1990 Dec; 162(6):1291-7. PubMed ID: 2172403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on simian viruses as possible contaminants of inactivated virus vaccines. I. Direct and serologic detection of simian adenovirus SV20 (author's transl)].
    von Mettenheim AE
    Zentralbl Bakteriol Orig A; 1975 Jul; 232(2-3):131-40. PubMed ID: 1179876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge.
    Taffs RE; Chernokhvostova YV; Dragunsky EM; Nomura T; Hioki K; Beuvery EC; Fitzgerald EA; Levenbook IS; Asher DM
    J Infect Dis; 1997 Feb; 175(2):441-4. PubMed ID: 9203668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of poliovirus type 3. A comparative study in children immunized with live, inactivated, or both types of poliovirus vaccines.
    Böttiger M
    Arch Gesamte Virusforsch; 1971; 35(2):251-5. PubMed ID: 4332939
    [No Abstract]   [Full Text] [Related]  

  • 13. IMMUNIZATION OF VOLUNTEERS WITH SOLUBLE ANTIGENS OF ADENOVIRUS TYPE 1.
    KASEL JA; HUBER M; LODA F; BANKS PA; KNIGHT V
    Proc Soc Exp Biol Med; 1964 Oct; 117():186-90. PubMed ID: 14219941
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines.
    Faden H; Duffy L; Sun M; Shuff C
    J Infect Dis; 1993 Aug; 168(2):452-4. PubMed ID: 8335983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poliovirus antibody status and the response to trivalent oral poliovirus vaccine in Norwegian school children.
    Orstavik I; Flugsrud LB; Lahelle O
    Acta Paediatr Scand; 1968 Sep; 57(5):405-8. PubMed ID: 4974044
    [No Abstract]   [Full Text] [Related]  

  • 16. Rheumatoid factor and immuno-conglutinin responses following various vaccinations.
    Aho K; Somer T; Salo OP
    Proc Soc Exp Biol Med; 1967 Jan; 124(1):229-33. PubMed ID: 6017774
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7.
    Top FH; Buescher EL; Bancroft WH; Russell PK
    J Infect Dis; 1971 Aug; 124(2):155-60. PubMed ID: 4330998
    [No Abstract]   [Full Text] [Related]  

  • 18. Adenovirus soluble antigen vaccine studies. I. Preparation and testing of adenovirus type 5 soluble antigen vaccines.
    Metzgar DP; Thomas WJ; Insalaco CS; DeSanctis AN; Beiler JM
    Proc Soc Exp Biol Med; 1968 Jul; 128(3):679-83. PubMed ID: 5668108
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccination with live type 4 adenovirus: evaluation of antibody response and protective efficacy.
    van der Veen J; Abarbanel MF; Oei KG
    Antonie Van Leeuwenhoek; 1969; 35(2):239. PubMed ID: 4316421
    [No Abstract]   [Full Text] [Related]  

  • 20. RESPONSE TO ONE DOSE OF TRIVALENT ORAL POLIOVACCINE IN CHILDREN PREVIOUSLY IMMUNISED WITH SALK VACCINE: A COMPARISON OF LIQUID VACCINE AND A CAPSULE PRESENTATION.
    BEALE AJ; DAVIES JR; THROWER AL
    Lancet; 1965 Apr; 1(7391):879-81. PubMed ID: 14272682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.